常茂生物(00954.HK)上半年预盈3800万元至4500万元同比大幅上升
格隆汇7月24日丨常茂生物(00954.HK)公布,集团很有可能录得2019年上半年归属于公司权益持有人的综合净利润约人民币3800万元至4500万元,较2018年同期约人民币1419.7万元大幅上升。
董事会认为,业绩增长主要是因为集团自2018年二季度完成丁烷法制顺酐改造工作,从源头上控制了生产成本,并取得了额外的能源效益。同时,各生产部门在节能减排、降耗增效以及提高劳动生产率上做了较多工作,为经济效益增加做出了一定贡献。另外,集团主要产品销售价格有所上升。双向作用促使本集团主要产品毛利率增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.